203 related articles for article (PubMed ID: 30156152)
21. Relationship of Advanced Glycation End Products With Cardiovascular Disease in Menopausal Women.
Pertynska-Marczewska M; Merhi Z
Reprod Sci; 2015 Jul; 22(7):774-82. PubMed ID: 25228634
[TBL] [Abstract][Full Text] [Related]
22. RAGE-aptamer Attenuates the Growth and Liver Metastasis of Malignant Melanoma in Nude Mice.
Nakamura N; Matsui T; Ishibashi Y; Sotokawauchi A; Fukami K; Higashimoto Y; Yamagishi SI
Mol Med; 2017 Nov; 23():295-306. PubMed ID: 29387865
[TBL] [Abstract][Full Text] [Related]
23. Regulation of advanced glycation end product (AGE)-receptor (RAGE) system by PPAR-gamma agonists and its implication in cardiovascular disease.
Yamagishi S; Nakamura K; Matsui T
Pharmacol Res; 2009 Sep; 60(3):174-8. PubMed ID: 19646657
[TBL] [Abstract][Full Text] [Related]
24. Possible involvement of advanced glycation end-products (AGEs) in the pathogenesis of Alzheimer's disease.
Takeuchi M; Yamagishi S
Curr Pharm Des; 2008; 14(10):973-8. PubMed ID: 18473848
[TBL] [Abstract][Full Text] [Related]
25. Targeting receptors of advanced glycation end products (RAGE): Preventing diabetes induced cancer and diabetic complications.
Chhipa AS; Borse SP; Baksi R; Lalotra S; Nivsarkar M
Pathol Res Pract; 2019 Nov; 215(11):152643. PubMed ID: 31564569
[TBL] [Abstract][Full Text] [Related]
26. Agents that block advanced glycation end product (AGE)-RAGE (receptor for AGEs)-oxidative stress system: a novel therapeutic strategy for diabetic vascular complications.
Yamagishi S; Nakamura K; Matsui T; Ueda S; Fukami K; Okuda S
Expert Opin Investig Drugs; 2008 Jul; 17(7):983-96. PubMed ID: 18549336
[TBL] [Abstract][Full Text] [Related]
27. DNA Aptamer Raised against Advanced Glycation End Products Improves Sperm Concentration, Motility, and Viability by Suppressing Receptors for Advanced Glycation End Product-Induced Oxidative Stress and Inflammation in the Testes of Diabetic Mice.
Mori Y; Terasaki M; Osaka N; Fujikawa T; Yashima H; Saito T; Kataoka Y; Ohara M; Higashimoto Y; Matsui T; Yamagishi SI
Int J Mol Sci; 2024 May; 25(11):. PubMed ID: 38892134
[TBL] [Abstract][Full Text] [Related]
28. Salvianolic Acid A Protects Against Diabetic Nephropathy through Ameliorating Glomerular Endothelial Dysfunction via Inhibiting AGE-RAGE Signaling.
Hou B; Qiang G; Zhao Y; Yang X; Chen X; Yan Y; Wang X; Liu C; Zhang L; Du G
Cell Physiol Biochem; 2017; 44(6):2378-2394. PubMed ID: 29262395
[TBL] [Abstract][Full Text] [Related]
29. Implication of advanced glycation end products (Ages) and their receptor (Rage) on myocardial contractile and mitochondrial functions.
Neviere R; Yu Y; Wang L; Tessier F; Boulanger E
Glycoconj J; 2016 Aug; 33(4):607-17. PubMed ID: 27277623
[TBL] [Abstract][Full Text] [Related]
30. Advanced Glycation End Products: Potential Mechanism and Therapeutic Target in Cardiovascular Complications under Diabetes.
Yang P; Feng J; Peng Q; Liu X; Fan Z
Oxid Med Cell Longev; 2019; 2019():9570616. PubMed ID: 31885827
[TBL] [Abstract][Full Text] [Related]
31. The role of AGEs in cardiovascular disease.
Jandeleit-Dahm K; Cooper ME
Curr Pharm Des; 2008; 14(10):979-86. PubMed ID: 18473849
[TBL] [Abstract][Full Text] [Related]
32. Therapeutic Interventions for Advanced Glycation-End Products and its Receptor- Mediated Cardiovascular Disease.
Prasad K; Tiwari S
Curr Pharm Des; 2017; 23(6):937-943. PubMed ID: 27719648
[TBL] [Abstract][Full Text] [Related]
33. Pathologic role of dietary advanced glycation end products in cardiometabolic disorders, and therapeutic intervention.
Yamagishi S; Matsui T
Nutrition; 2016 Feb; 32(2):157-65. PubMed ID: 26602289
[TBL] [Abstract][Full Text] [Related]
34. Advanced glycation end products (AGEs) on the surface of diabetic erythrocytes bind to the vessel wall via a specific receptor inducing oxidant stress in the vasculature: a link between surface-associated AGEs and diabetic complications.
Wautier JL; Wautier MP; Schmidt AM; Anderson GM; Hori O; Zoukourian C; Capron L; Chappey O; Yan SD; Brett J
Proc Natl Acad Sci U S A; 1994 Aug; 91(16):7742-6. PubMed ID: 8052654
[TBL] [Abstract][Full Text] [Related]
35. DNA aptamer raised against advanced glycation end products inhibits neointimal hyperplasia in balloon-injured rat carotid arteries.
Ojima A; Oda E; Higashimoto Y; Matsui T; Yamagishi S
Int J Cardiol; 2014 Feb; 171(3):443-6. PubMed ID: 24439773
[TBL] [Abstract][Full Text] [Related]
36. Protective role of sulphoraphane against vascular complications in diabetes.
Yamagishi S; Matsui T
Pharm Biol; 2016 Oct; 54(10):2329-39. PubMed ID: 26841240
[TBL] [Abstract][Full Text] [Related]
37. [Therapeutic intervention in diseases with advanced glycation end products in their pathogenesis].
Zuwała-Jagiełło J
Pol Merkur Lekarski; 2009 Aug; 27(158):152-6. PubMed ID: 19856885
[TBL] [Abstract][Full Text] [Related]
38. RAGE: A potential therapeutic target during FGF1 treatment of diabetes-mediated liver injury.
Zheng P; Tang Z; Xiong J; Wang B; Xu J; Chen L; Cai S; Wu C; Ye L; Xu K; Chen Z; Wu Y; Xiao J
J Cell Mol Med; 2021 May; 25(10):4776-4785. PubMed ID: 33788387
[TBL] [Abstract][Full Text] [Related]
39. Food-derived advanced glycation end products (AGEs): a novel therapeutic target for various disorders.
Yamagishi S; Ueda S; Okuda S
Curr Pharm Des; 2007; 13(27):2832-6. PubMed ID: 17897026
[TBL] [Abstract][Full Text] [Related]
40. Advanced glycation end products and insulin resistance.
Unoki H; Yamagishi S
Curr Pharm Des; 2008; 14(10):987-9. PubMed ID: 18473850
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
